Search

Your search keyword '"Complement C5a analysis"' showing total 174 results

Search Constraints

Start Over You searched for: Descriptor "Complement C5a analysis" Remove constraint Descriptor: "Complement C5a analysis"
174 results on '"Complement C5a analysis"'

Search Results

1. Clinical values of serum C5a in Alzheimer's disease patients with different dementia stages.

2. Enhancing prognostic prediction of invasive candidiasis among cancer patients with a serum C5a-based scoring model.

3. Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer's disease of different severity.

4. Pseudomonas aeruginosa adaptation in cystic fibrosis patients increases C5a levels and promotes neutrophil recruitment.

5. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.

6. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.

7. Complement Factor C5a Is Increased in Blood of Patients with Abdominal Aortic Aneurysm and Has Prognostic Potential for Aneurysm Growth.

8. Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome.

9. Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration.

10. Variation in the hemostatic complement (C5a) responses to in vitro nitrogen bubbles in monodontids and phocids.

11. Complement protein levels and MBL2 polymorphisms are associated with dengue and disease severity.

12. Absence of complement factor H reduces physical performance in C57BL6 mice.

13. Complement activation in patients with COVID-19: A novel therapeutic target.

14. The Identification of Immune-Related Plasma Proteins Associated with Spontaneous Preterm Delivery and Intra-Amniotic Infection in Women with Premature Cervical Dilation or an Asymptomatic Short Cervix.

15. Biomarkers and newer laboratory investigations in the diagnosis of sepsis.

16. Complement activation products in the circulation and urine of primary membranous nephropathy.

17. Effect of preoperative inhaled budesonide on pulmonary injury after cardiopulmonary bypass: A randomized pilot study.

18. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma.

19. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?

20. Plasma inflammatory and immune proteins as predictors of intra-amniotic infection and spontaneous preterm delivery in women with preterm labor: a retrospective study.

21. Serum complement factor 5a levels are associated with nonalcoholic fatty liver disease in obese children.

22. Elizabethkingia miricola as an opportunistic oral pathogen associated with superinfectious complications in humoral immunodeficiency: a case report.

23. Therapeutic hypothermia modulates complement factor C3a and C5a levels in a rat model of hypoxic ischemic encephalopathy.

24. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis.

25. Complement 5a is an indicator of significant fibrosis and earlier cirrhosis in patients chronically infected with hepatitis B virus.

26. Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma.

27. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.

28. Correlations between complement system's activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia.

29. C5aR inhibition in the early inflammatory phase does not affect bone regeneration in a model of uneventful fracture healing.

30. Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood.

31. [Association between protective effect of Liuwei Wuling tablets against acute liver injury and its inhibitory effect on cytoplasmic translocation of high-mobility group box-1 in hepatocytes in mice].

32. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease.

33. The Anti-Microbial Peptide LL-37/CRAMP Is Elevated in Patients with Liver Diseases and Acts as a Protective Factor during Mouse Liver Injury.

34. IFN-γ-producing NKT cells exacerbate sepsis by enhancing C5a generation via IL-10-mediated inhibition of CD55 expression on neutrophils.

35. Complement activation products C5a and sC5b-9 are associated with low-grade inflammation and endothelial dysfunction, but not with atherosclerosis in a cross-sectional analysis: the CODAM study.

36. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.

37. [Clinical relevance of biomarkers in allergic rhinitis].

38. Complement mediates a primed inflammatory response after traumatic lung injury.

39. Salivary levels of secretary IgA, C5a and alpha 1-antitrypsin in sulfur mustard exposed patients 20 years after the exposure, Sardasht-Iran Cohort Study (SICS).

40. Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria.

41. Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia.

42. C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay.

43. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation.

44. Roles of Gr-1+ leukocytes in postincisional nociceptive sensitization and inflammation.

45. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

46. [Anaphylatoxins C3a, C4a, C5a].

47. Complement factor C5a in acute exacerbation of Chronic Obstructive Pulmonary Disease.

48. Complement activation in emergency department patients with severe sepsis.

49. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a.

50. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.

Catalog

Books, media, physical & digital resources